Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03768531 |
Recruitment Status :
Withdrawn
(No subjects were enrolled)
First Posted : December 7, 2018
Last Update Posted : April 13, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Resectable Biliary Tract Cancer | Drug: Nivolumab Drug: Cabrilizumab | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Safety and Tolerability Study of Combination Nivolumab and Cabiralizumab as Neoadjuvant and Adjuvant Therapy for Resectable Biliary Tract Cancer |
Actual Study Start Date : | June 14, 2019 |
Estimated Primary Completion Date : | January 2023 |
Estimated Study Completion Date : | January 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm A: Nivolumab |
Drug: Nivolumab
Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
Other Name: OPDIVO; BMS-936558-01 |
Experimental: Arm B: Nivolumab and Cabrilizumab
Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes, a 30 minute rest, followed by cabiralizumab every 2 weeks. (Cycle length 2 weeks).
|
Drug: Nivolumab
Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
Other Name: OPDIVO; BMS-936558-01 Drug: Cabrilizumab Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).
Other Name: FPA008, BMS-986227 |
- Number of participants experiencing study drug-related toxicities [ Time Frame: 4 years ]Number of participants experiencing drug-related adverse events as defined by CTCAE v5.0
- Overall survival (OS) [ Time Frame: 4 years ]Number of months from the date of first treatment until death or end of follow-up.
- Disease free survival (DFS) [ Time Frame: up to 4 years ]Number of months until disease recurrence.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Has confirmed biliary tract cancer
- Ability to understand and willingness to sign a written informed consent document.
- Age ≥18 years
- Have biopsiable disease
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Patient must have adequate organ function defined by the study-specified laboratory tests.
- Must use acceptable form of birth control while on study.
Exclusion Criteria:
- Has active autoimmune disease that requires systemic treatment.
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years or that is expected to require active treatment within two years.
- Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.).
- Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
- Has evidence of an uncontrolled, active infection requiring parenteral anti-bacterial, anti-viral or anti-fungal therapy ≤ 7 days prior to administration of study medication.
- Has received a blood transfusion within 72 hours prior to first dose of study drug administration
- Unwilling or unable to follow the study schedule for any reason.
- Major surgery within 4 weeks prior to initiation of study treatment.
- Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant muscle disorders or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant or breastfeeding women.
- Have known history of infection with HIV, hepatitis B, or hepatitis C.
- Received any prophylactic vaccine within 30 days of first dose of study drug treatment.
- Has a history of allergy to study treatments or any of its components of the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03768531
Principal Investigator: | Adrian Murphy, MD | Johns Hopkins Medical Institution |
Responsible Party: | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
ClinicalTrials.gov Identifier: | NCT03768531 |
Other Study ID Numbers: |
J18162 IRB00185328 ( Other Identifier: JHM IRB ) |
First Posted: | December 7, 2018 Key Record Dates |
Last Update Posted: | April 13, 2020 |
Last Verified: | April 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Nivolumab Cabiralizumab Immunotherapy Anti-PD-1 Anti-CSF-1R |
Biliary tract cancers (BTC) Neoadjuvant chemotherapy Adjuvant chemotherapy Tumor microenvironment |
Biliary Tract Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Biliary Tract Diseases Digestive System Diseases |
Nivolumab Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |